Esperion Therapeutics’ (NASDAQ:ESPR) Buy Rating Reiterated at Stifel Nicolaus
Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at Stifel Nicolaus in a research report issued on Thursday. They currently have a $70.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $60.00. Stifel Nicolaus’ price objective would indicate a potential upside of 38.50% from the company’s previous close.
ESPR has been the topic of several other reports. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, June 25th. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Tuesday. Finally, Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $41.16.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at 50.54 on Thursday. The company’s market cap is $1.14 billion. The firm’s 50-day moving average is $44.47 and its 200-day moving average is $33.65. Esperion Therapeutics has a one year low of $9.40 and a one year high of $55.17.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by $0.25. During the same quarter in the previous year, the company posted ($0.62) EPS. On average, equities analysts anticipate that Esperion Therapeutics will post ($7.18) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Esperion Therapeutics’ (NASDAQ:ESPR) Buy Rating Reiterated at Stifel Nicolaus” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/esperion-therapeutics-nasdaqespr-buy-rating-reiterated-at-stifel-nicolaus/1467367.html.
Hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new stake in shares of Esperion Therapeutics during the first quarter worth about $158,000. C WorldWide Group Holding A S bought a new stake in shares of Esperion Therapeutics during the first quarter worth about $162,000. Princeton Alpha Management LP bought a new stake in shares of Esperion Therapeutics during the first quarter worth about $205,000. Bank of Montreal Can increased its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares in the last quarter. Finally, Aperio Group LLC bought a new stake in shares of Esperion Therapeutics during the second quarter worth about $249,000. Institutional investors own 85.20% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.